Thyroid Eye Disease Patients Gain New FDA-Approved Drug
Adults with thyroid eye disease now have a new treatment option following an FDA approval for the drug Enspryng.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Should the FDA accelerate approval processes for new treatments for rare autoimmune conditions?
The FDA has granted approval to Roche Holding for the use of Enspryng to treat thyroid eye disease in adults. The decision, which marks an expansion of the drug's approved uses, follows results from two late-stage clinical studies.
Why it matters
This approval provides a new treatment option for adults managing thyroid eye disease, a rare autoimmune condition. The development expands the clinical utility of Enspryng, which was previously authorized for use in another autoimmune disorder.
The FDA based this approval on findings from two late-stage clinical studies. While the drug is now cleared for thyroid eye disease, specific efficacy benchmarks from these trials remain pending further public disclosure.
The players
Roche Holding
A global pharmaceutical company focused on the development of treatments for rare neurological, autoimmune, and inflammatory diseases.
FDA
The federal agency responsible for protecting public health by regulating the safety and efficacy of medical treatments in the United States.
The details
Enspryng is a treatment designed for rare autoimmune conditions that involve inflammatory processes. The FDA's recent decision allows its use in adults with thyroid eye disease, adding to its previous 2020 authorization for neuromyelitis optica spectrum disorder. The manufacturer is also currently seeking regulatory approval for the drug's use in myelin oligodendrocyte glycoprotein antibody-associated disease.
Timeline
The FDA first authorized Enspryng for neuromyelitis optica spectrum disorder in 2020.
The FDA approved Enspryng for the treatment of thyroid eye disease on October 16, 2026.
Health Landscape
This approval marks a significant step in the broader effort to address rare autoimmune conditions using established biological therapies. It follows the established track record of Roche's auto-immune inflammatory research program in repurposing existing biologics for related rare conditions.
If you are currently managing thyroid eye disease, this approval may represent a new option worth discussing with your doctor. Always consult with your primary care provider or specialist to understand how new regulatory approvals fit into your personal treatment plan.
The takeaway
The FDA has expanded the approved use of Enspryng to include treatment for adults with thyroid eye disease. Patients interested in learning about new treatment options should start a conversation with their specialist to discuss the latest available therapies.
Further reading
For more information on the management of rare conditions, visit our Cancer section.
Live Poll
Should the FDA accelerate approval processes for new treatments for rare autoimmune conditions?
